文献速递前列腺癌

多参数磁共振与系统穿刺对前列腺癌术后生化复发的预测价值

Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
PubMed 文献 · Eur Urol Oncol · 2020-08-23

本研究纳入804例经MRI靶向联合系统穿刺确诊并接受根治性前列腺切除术的前列腺癌患者,中位随访28个月,89例出现生化复发。基于PSA、PI-RADS评分、精囊侵犯、指标病灶最大径、MRI靶向穿刺分级分组及系统穿刺临床显著癌构建的模型在预测36个月生化复发时区分度达77%,优于EAU风险分组(62%)和CAPRA评分(60%)。

要点

  • mpMRI指标病灶最大径和精囊侵犯与术后生化复发独立相关。
  • 系统穿刺发现临床显著前列腺癌(分级分组>2)亦为生化复发预测因子。
  • 整合mpMRI与穿刺变量的模型预测36个月生化复发区分度达77%。

核心结论

  • 采用纳入mpMRI及MRI靶向穿刺变量和同期系统穿刺的预测模型,可提升识别术后早期高复发风险患者的能力。

研究设计与样本

  • 回顾性队列研究,纳入804例临床怀疑前列腺癌且mpMRI阳性、经MRI靶向联合同期系统穿刺确诊并接受根治性前列腺切除术的患者。

主要发现

  • 中位随访28个月(IQR 25-29),89例发生生化复发,36个月无生化复发生存率为89%。
  • mpMRI指标病灶最大径、精囊侵犯及系统穿刺临床显著前列腺癌(分级分组>2)均与生化复发相关(所有p≤0.03)。
  • 基于PSA、PI-RADS评分、mpMRI精囊侵犯、指标病灶直径、MRI靶向穿刺分级分组及系统穿刺临床显著癌的模型区分度达77%,高于EAU风险分组(62%)和CAPRA评分(60%)。
  • 该模型内部验证校准良好,在预测36个月生化复发时阈值风险0%至30%区间净获益最高。

关键数值与推荐

  • 生化复发定义为术后两次前列腺特异性抗原(PSA)值≥0.2ng/ml。
  • 系统穿刺临床显著前列腺癌定义为分级分组>2。

临床怎么用

  • 对于经MRI靶向联合系统穿刺确诊并接受根治性前列腺切除术的患者,可考虑使用整合mpMRI和穿刺变量的模型评估术后早期生化复发风险。

局限性

  • 随访时间较短(中位28个月),仅进行内部验证,需外部验证确认模型泛化能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prognostic role of multiparametric magnetic resonance imaging (mpMRI) and systematic biopsy in predicting biochemical recurrence (BCR) after radical prostatectomy (RP) in prostate cancer (PCa) patients has not been addressed yet. OBJECTIVE: To develop a risk tool predicting BCR after RP in patients diagnosed with magnetic resonance imaging (MRI)-targeted biopsy. DESIGN, SETTING, AND PARTICIPANTS: A total of 804 patients with a clinical suspicion of PCa and positive mpMRI diagnosed with MRI-targeted plus concomitant systematic biopsy treated with RP were identified. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: The outcome was represented by BCR defined as two prostate-specific antigen (PSA) values ≥0.2ng/ml after surgery. Multivariable Cox regression analyses assessed the predictors of BCR. A risk tool model based on imaging and biopsy parameters was developed and validated internally. The c-index, calibration plot, and decision curve analyses were used to assess discrimination, calibration, and the net benefit associated with its use in predicting BCR at 36 mo. RESULTS AND LIMITATIONS: Median (interquartile range) follow-up was 28 (25-29) mo, and 89 patients experienced BCR. The 36-mo BCR-free survival rate was 89%. The maximum diameter of the index lesion and seminal vesicle invasion (SVI) at mpMRI as well as the presence of clinically significant PCa at systematic biopsy (defined as a grade group of >2) were associated with BCR (all p≤0.03). A model based on PSA, Prostate Imaging Reporting and Data System score, SVI at mpMRI, diameter of the index lesion, grade group at MRI-targeted biopsy, and clinically significant PCa at systematic biopsy achieved the highest discrimination (77%) among all clinical models, as well as the European Association of Urology risk groups (62%) and the Cancer of the Prostate Risk Assessment (CAPRA) score (60%). This tool was characterized by excellent calibration at internal validation and the highest net benefit when predicting BCR for the threshold risk between 0% and 30%. CONCLUSIONS: The adoption of predictive models accounting for mpMRI and MRI-targeted biopsy-derived variables and concomitant systematic biopsy would improve clinicians' ability to identify patients at a higher risk of early recurrence after surgery. PATIENT SUMMARY: The use of information obtained at multiparametric magnetic resonance imaging (mpMRI), and MRI-targeted and concomitant systematic biopsy would improve clinicians' ability to identify prostate cancer patients at a higher risk of experiencing early biochemical recurrence after surgery.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Gandaglia G, Ploussard G, Valerio M, et al. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy. Eur Urol Oncol. 2020. PMID: 32847747. doi:10.1016/j.euo.2020.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。